Blog Header

By: Oncostellae

9 Jun 2021
Cinco firmas gallegas socias de Bioga acuden a BIO Digital 2021, la principal feria biotech del mundo

junio 11, 2021

Oncostellae, Celtarys Research, SunRock Biopharma, Arjuna Therapeutics y Key Biological estarán en la cita ‘on line’ que abordará cómo el sector bio…

Read More
25 Mar 2021
Jornada de Presentación de Resultados del Proyecto IO4COLON


marzo 24, 2021

ONCOSTELLAE se complace en invitaros a la jornada de cierre del proyecto IO4COLON, “Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos…

Read More
23-25 Mar 2020
Oncostellae participates at the BIO-Europe partnering conference in Paris


febrero 22, 2020

Oncostellae will assist at the 14th Annual International Partnering Conference during the BIO-Europe Spring event that takes place from March 23-25,…

Read More
February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis
febrero 21, 2020

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More
11 October 2019
IO4COLON project progress




febrero 21, 2020

Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos en tratamiento de cáncer de colon. El pasado viernes (11 de octubre…

Read More
May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing
febrero 20, 2020

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More
10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

marzo 24, 2019

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More
23 Jul 2018
Oncostellae initiated clinical development of OST-122


marzo 24, 2019

Oncostellae has started today a first-in-human study of OST-122, its novel, gut-restricted Jak3/Tyk2 inhibitor that is being developed for the local…

Read More
22 Feb 2019
IO4COLON Project Presentation


febrero 23, 2019

Last 22th of February at 12:00 pm was celebrated the Presentation of IO4COLON Project in the CIQUS Research Center We are pleased…

Read More
25-27 Sep 2018
Oncostellae participates at Biospain 2018 in Seville


julio 19, 2018

Oncostellae participates at the 2018 Biospain congress that takes place from 25th to 27th of September  2018  in the Fibes Exhibition &…

Read More